QuidelOrtho Corporation with ticker code (QDEL) now have 7 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $61.00 and $38.00 suggesting an average analyst share price target price of $51.14. (at the time of writing). Given that the stocks previous close was at $41.49 this would imply there is now a potential upside of 23.3%. The 50 day moving average now sits at $43.05 and the 200 moving average now moves to $41.11. The market capitalization for the company is 2.82B. The stock price is currently at: $41.89 USD
The potential market cap would be $3,472,861,724 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $41.41 and a 0.38% return on assets.
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its capabilities include immunoassay and molecular testing, clinical chemistry and transfusion medicine. The Company’s business units include Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology, Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform, VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells, InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel, QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage, Virena, and Vitros.
